← Back to headlines
Blackstone Commits $400 Million with Teva for Duvakitug Clinical Development
Blackstone (BX) has committed $400 million in partnership with Teva Pharmaceutical Industries to advance the clinical development of Duvakitug.
13 Mar, 17:23 — 13 Mar, 17:23
Sources
Showing 1 of 1 sources
Related Stories
August Manufacturing PMI Data Reveals Divergent Global Economic Performance
29m ago
Shein’s Hong Kong IPO Debut Underwhelms Amid Geopolitical Risks and New Fashion Levies
31m ago
Wall Street Futures Drop as Rising Yields and Oil Prices Weigh on Markets
45m ago
IKEA Launches €1.2 Billion Price Cut Campaign Across Europe
51m ago